Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1371 of 1371 results for patients and public

  1. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  2. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 13 November 2024

    Interventional procedures guidance
    In development

  3. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Drug eluting stents for treating coronary heart disease: late stage assessment

    In development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    In development

  6. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  7. Palopegteriparatide for treating chronic hypoparathyroidism ID6380

    In development [GID-TA11454] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  9. Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer

    In development [GID-DG10075] Expected publication date: 09 May 2024

    Diagnostics guidance
    In development

  10. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. News

    home rather than hospital and improves the length and quality of life for patients. 24 April 2024

  12. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  13. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  14. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  15. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Voxelotor for treating sickle cell disease [ID1403]

    In development [GID-TA10505] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  17. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]

    In development [GID-TA10834] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  18. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  21. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued